Regulatory & Legal

With cardiac arrest striking every 9 minutes, a Québec foundation calls for a new law, citing a 29,000-defibrillator gap to ensure survival isn't left to chance.

Millions more Americans gain access to ABLEnow accounts in 2026 with expanded eligibility, higher savings limits, and a move to a new, modern platform.

Facing a legacy of recalls from its predecessor, medical device firm Advita Ortho launches a new quality initiative. Is it a true turnaround?

A Connecticut institute is turning community-led research on health, education, and wealth disparities into policy briefs aimed at driving legislative change.

With a new executive and an advanced monitoring solution, Picarro is making a major play to help the oil and gas industry shift to proactive emissions control.

A new digital platform lets lenders instantly quote and buy flood insurance, tackling a major roadblock in home loans amid rising climate risks.

BNSF Railway unveils a massive $3.6 billion capital plan for 2026, focusing on critical maintenance and strategic expansions in California and Arizona.

A historic deal will double US aluminum output, creating thousands of jobs. But the project's success is tied to controversial tariffs and green tech promises.

Sprott Physical Uranium Trust can now raise another $1 billion to buy physical uranium, tightening its grip on a market already facing supply shortages.

A new study confirms AI can detect major heart conditions from one brief ultrasound clip, empowering any clinician to perform life-saving cardiac screening.

RegTech leader Comply secures coveted ISO 27001 certification, launching a new Trust Center to prove its commitment to enterprise-grade data protection.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

In a major IP victory, Reed Semiconductor had a Monolithic Power Systems patent voided by the USPTO. Now, Reed is hinting at its own infringement claims.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

Biotech firm Tharimmune is now a Super Validator on the Canton Network, a bold move blending clinical research with institutional digital finance.

Colombia's Mineros S.A. shines on the TSX30 and BVC with a 903% return, yet management argues it's deeply undervalued compared to its peers.

China's Zijin Gold is acquiring Canada's Allied Gold in an all-cash deal, delivering a major premium to shareholders and securing key African assets.

Labrador Gold faces a proxy fight as management's hybrid investment plan clashes with a dissident's push for a traditional exploration focus.

A S$1.06 million donation aims to fuse ancient TCM wisdom with modern science, boosting Singapore's role as a global healthcare innovation hub.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.